Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Child

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
The New England Journal of Medicine|October 8, 2025
Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes. ReplyJulio Rosenstock, Molly C Carr, Christopher J Child
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 16, 2020
NASAL GLUCAGON DELIVERY IS MORE SUCCESSFUL THAN INJECTABLE DELIVERY: A SIMULATED SEVERE HYPOGLYCEMIA RESCUEJulie A Settles, Gregg Francis Gerety, Erik Spaepen, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 9, 2022
Nasal Glucagon Is Easier to Use and More Preferred and Needs Less Effort to Administer Than Injectable Glucagon: User Perceptions of Glucagon Administration During Severe Hypoglycemia SimulationJulie Settles, Deborah Hinnen, Erik Spaepen, et al.
European Journal of Endocrinology|March 27, 2015
Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications StudyChristopher J Child, Daniel Conroy, Alan G Zimmermann, et al.
Hormone Research in Paediatrics|February 26, 2016
Assessment of Primary Cancer Incidence in Growth Hormone-Treated Children: Comparison of a Multinational Prospective Observational Study with Population DatabasesChristopher J Child, Alan G Zimmermann, Nan Jia, et al.
The Journal of Clinical Endocrinology and Metabolism|April 15, 2011
Prevalence and incidence of diabetes mellitus in GH-treated children and adolescents: analysis from the GeNeSIS observational research programChristopher J Child, Alan G Zimmermann, Robin S Scott, et al.
The Journal of Clinical Endocrinology and Metabolism|June 3, 2017
Mortality in Children Receiving Growth Hormone Treatment of Growth Disorders: Data From the Genetics and Neuroendocrinology of Short Stature International StudyCharmian A Quigley, Christopher J Child, Alan G Zimmermann, et al.
Diabetes, Obesity & Metabolism|December 4, 2025
Low immunogenicity of insulin efsitora alfa in participants with type 1 and type 2 diabetes mellitusYun Wang, Sihe Wang, Wei Wang, et al.
Diabetes, Obesity & Metabolism|March 10, 2022
Previously unrecognized risk factors for severe hypoglycaemia requiring emergency medical care in insulin-treated type 2 diabetes: Results from a real-world nested case-control studyJulie Settles, Hong Kan, Christopher J Child, et al.
The New England Journal of Medicine|June 23, 2025
Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin TherapyJulio Rosenstock, Timothy Bailey, Lisa Connery, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
The New England Journal of Medicine|October 8, 2025
Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes. ReplyJulio Rosenstock, Molly C Carr, Christopher J Child
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 16, 2020
NASAL GLUCAGON DELIVERY IS MORE SUCCESSFUL THAN INJECTABLE DELIVERY: A SIMULATED SEVERE HYPOGLYCEMIA RESCUEJulie A Settles, Gregg Francis Gerety, Erik Spaepen, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 9, 2022
Nasal Glucagon Is Easier to Use and More Preferred and Needs Less Effort to Administer Than Injectable Glucagon: User Perceptions of Glucagon Administration During Severe Hypoglycemia SimulationJulie Settles, Deborah Hinnen, Erik Spaepen, et al.
European Journal of Endocrinology|March 27, 2015
Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications StudyChristopher J Child, Daniel Conroy, Alan G Zimmermann, et al.
Hormone Research in Paediatrics|February 26, 2016
Assessment of Primary Cancer Incidence in Growth Hormone-Treated Children: Comparison of a Multinational Prospective Observational Study with Population DatabasesChristopher J Child, Alan G Zimmermann, Nan Jia, et al.
The Journal of Clinical Endocrinology and Metabolism|April 15, 2011
Prevalence and incidence of diabetes mellitus in GH-treated children and adolescents: analysis from the GeNeSIS observational research programChristopher J Child, Alan G Zimmermann, Robin S Scott, et al.
The Journal of Clinical Endocrinology and Metabolism|June 3, 2017
Mortality in Children Receiving Growth Hormone Treatment of Growth Disorders: Data From the Genetics and Neuroendocrinology of Short Stature International StudyCharmian A Quigley, Christopher J Child, Alan G Zimmermann, et al.
Diabetes, Obesity & Metabolism|December 4, 2025
Low immunogenicity of insulin efsitora alfa in participants with type 1 and type 2 diabetes mellitusYun Wang, Sihe Wang, Wei Wang, et al.
Diabetes, Obesity & Metabolism|March 10, 2022
Previously unrecognized risk factors for severe hypoglycaemia requiring emergency medical care in insulin-treated type 2 diabetes: Results from a real-world nested case-control studyJulie Settles, Hong Kan, Christopher J Child, et al.
The New England Journal of Medicine|June 23, 2025
Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin TherapyJulio Rosenstock, Timothy Bailey, Lisa Connery, et al.
Pageof 4